Work

Abstract 4364312: Laroprovstat (AZD0780) an oral, small molecule PCSK9 inhibitor demonstrates improvements in the lipid profile in participants with hypercholesterolemia: Results from a Phase 1 study

Year: 2025

Type: conference-abstract

Source: Circulation

DOI: 10.1161/circ.152.suppl_3.4364312

Authors: Rick Vega, Hongtao Yu, April Barbour, Tasso Miliotis, Maria Ryaboshapkina, Marielle Andersson, Debra Carter, Niklas Bergh, Jaya Rosenmeier

Institutions: AstraZeneca (Sweden), AstraZeneca (United States)

Language: English

Topic: Lipoproteins and Cardiovascular Health

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4415799326

Cites:

Cited by:

Related to: